ArticleAntimicrobial agents and chemotherapy2012
Antibacterial activities of iron chelators against common nosocomial pathogens.
Article in Antimicrobial agents and chemotherapy, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 75 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
75 citing papers in PubMed.
- Desferrioxamine Sharing among Microalgae-Associated Bacteria Enhances Iron-Limited Inhibition ofJournal of natural products · 2026Article
- Article
- Comparative and Subtractive Genomics Analysis of Multidrug-ResistantInternational journal of microbiology · 2026Article
- The in vitro activity of iron chelator deferiprone against Candida (Candidozyma) auris in combination with antifungal agents.Medical mycology · 2025Article
- AmpC β-Lactamase-Producing Microorganisms in South American Hospitals: A Meta-Regression Analysis, Meta-Analysis, and Review of Prevalence.Tropical medicine and infectious disease · 2025Review
- VLX600, an anticancer iron chelator, exerts antimicrobial effects onMicrobiology spectrum · 2025Article
- Interactions Between Iron Metabolism and the Endocannabinoid System in Bacterial Infections.Antibiotics (Basel, Switzerland) · 2025Review
- Exploiting haem-iron dependence of nontypeableFrontiers in cellular and infection microbiology · 2025Review
- Predisposing Factors to Infections in Thalassemia Syndrome Patients.Mediterranean journal of hematology and infectious diseases · 2025Article
- Antimicrobial activity of iron-depriving pyoverdines against human opportunistic pathogens.eLife · 2024Article
- Pathogenicity and virulence ofVirulence · 2024Review
- Radiotracers for in situ infection imaging: Experimental considerations for in vitro microbial uptake of gallium-68-labeled siderophores.Diagnostic microbiology and infectious disease · 2024Article
- Differential gut microbiota composition in β-Thalassemia patients and its correlation with iron overload.Scientific reports · 2024Article
- A Preliminary Study on the Effect of Deferoxamine on the Disruption of Bacterial Biofilms and Antimicrobial Resistance.Turkish journal of pharmaceutical sciences · 2024Article
- Ironing out Persisters? Revisiting the Iron Chelation Strategy to Target Planktonic Bacterial Persisters Harboured in Carbapenem-ResistantMicroorganisms · 2024Article
- Biofilm Microenvironment Activated Antibiotic Adjuvant for Implant-Associated Infections by Systematic Iron Metabolism Interference.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- The application of synthetic antibacterial minerals to combat topical infections: exploring a mouse model of MRSA infection.Scientific reports · 2024Article
- Effects of deferoxamine on intrinsic colistin resistance ofExperimental and therapeutic medicine · 2023Article
- Iron bioavailability regulates Pseudomonas aeruginosa interspecies interactions through type VI secretion expression.Cell reports · 2023Article
- Synthesis, Photochemistry, Computational Study and Potential Application of New Styryl-Thiophene and Naphtho-Thiophene Benzylamines.International journal of molecular sciences · 2022Article
15 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The activities of iron chelators (deferoxamine, deferiprone, Apo6619, and VK28) were evaluated against type strains of Acinetobacter baumannii, Pseudomonas aeruginosa, Staphylococcus aureus, Klebsiella pneumoniae, and Escherichia coli. Deferiprone, Apo6619, and VK28 each inhibited growth in standard and RPMI tissue culture medium, while deferoxamine had no effect. Additionally, time-kill assays revealed that VK28 had a bacteriostatic effect against S. aureus. Therefore, these newly developed iron chelators might provide a nontraditional approach for treatment of bacterial infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.